Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
60.85
+1.87 (3.17%)
At close: May 12, 2025, 4:00 PM
59.09
-1.76 (-2.89%)
After-hours: May 12, 2025, 6:52 PM EDT
Incyte Revenue
Incyte had revenue of $1.05B in the quarter ending March 31, 2025, with 19.53% growth. This brings the company's revenue in the last twelve months to $4.41B, up 17.13% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.41B
Revenue Growth
+17.13%
P/S Ratio
2.75
Revenue / Employee
$1,686,368
Employees
2,617
Market Cap
11.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
INCY News
- 12 hours ago - 20 stocks of companies showing excellent earnings-season trends even as the economy cools - Market Watch
- 5 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 11 days ago - Incyte to Present at Upcoming Investor Conference - Business Wire
- 13 days ago - Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Incyte raises 2025 sales forecast for blood cancer drug after solid quarter - Reuters
- 13 days ago - Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs - Business Wire
- 17 days ago - Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 - Business Wire
- 19 days ago - Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire